PREHAREC: Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative

Sponsor
Corporacion Parc Tauli (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05286086
Collaborator
(none)
50
1
2
36
1.4

Study Details

Study Description

Brief Summary

Control of the effect of prehabilitation on postoperative morbidity, assessed by the Comprehensive Complication Index (CCI), in patients diagnosed with rectal cancer that will receive neoadjuvant Quimiorradiotherapy (NCRT) and subsequent surgery, performed at the beginning of NCRT or before surgery.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: prehabilitation
N/A

Detailed Description

According to the annual report of the Spanish Medical Oncology Association (SEOM), in Spain and without differentiating by sex, colorectal cancer will be the cancer with the highest incidence by 2021; with 43.581 new cases estimated for such year, 14.209 of these will be of rectal cancer. In rectal cancer, surgery remains the cornerstone; however, it is already known that local recurrences are frequent. That is why one of the main milestones rectal cancer treatment, is the multimodal therapy approach. It consists of implementing a neoadjuvant chemoradiotherapy treatment (NCRT) prior to surgical intervention. With this, local control of the disease is achieved, metastases are reduced have resulted in a five-year survival. Subsequently, depending on the definitive pathological results, patients should also complete treatment with postoperative chemotherapy. It is known that patients undergoing neoadjuvant treatment experience a wide variety of side effects, which can cause loss of muscle and cardiovascular function, loss of their functional capacity and increased fatigue. This worsens the quality of life of the patient and can sometimes cause the interruption of neoadjuvant treatment and have repercussions on the prognosis. Not only do these side effects affect the course of neoadjuvant treatment, but also declines the physiological reserve, making the patient arrive in sub-optimal conditions for surgery. This has an impact on postoperative morbidity and mortality, and secondarily, in the increase of hospital stay.

The concept of functional capacity appears ¨as the nutritional, physical and emotional state that a person has to face a stressful situation, such as surgical treatment. It is believed that if functional capacity is enhanced, postoperative morbidity can be reduced and the patient's recovery can also be improved. That is why trimodal programs are created, specifically selected for their potential cumulative or synergistic effects on health outcomes to prepare patients to face surgery at all three levels. These programs are known as prehabilitation.

Currently there are studies that show that prehabilitation improves the results of patients who must undergo different major surgical procedures, among them in colorectal surgery. Our group has recently presented a study that shows that trimodal prehabilitation contributes to reducing postoperative morbidity and overall hospital stay in patients operated on for colorectal neoplasia. There are also systematic reviews that conclude that prehabilitated patients who must undergo major surgery (speaking of 435 patients and 9 studies) present a decrease in the incidence of major postoperative complications. On the other hand, there are studies that show that prehabilitation in patients who must receive neoadjuvant therapy reduces the decrease of functional capacity that treatment produces on patients. As also shown by the Rex Trial, a randomized study on 48 patients. In an attempt to unite the two lines start the study, it will be a novel one , with only two previously published studies in this area. The intention is demonstrate that when prehabilitation is started before commencing neoadjuvant therapy in patients who are diagnosed with rectal cancer and who are subject to neoadjuvant therapy, will reduce the effect on functional capacity, and that patients will present less postoperative morbidity and better postoperative recovery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective , unicentric, randomizedProspective , unicentric, randomized
Masking:
None (Open Label)
Masking Description:
due to the characteristics of the study, it is not possible to perform masking
Primary Purpose:
Other
Official Title:
Randomized Controlled Trial Comparing the Effect of a Multimodal Prehabilitation Program During Neoadjuvant Treatment Versus a Multimodal Prehabilitation After Neoadjuvant Treatment for Patients Undergoing Resection of Rectal Cancer.
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2022
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: PREHAB-PREOP

PREHABILITATION BEFORE SURGERY

Behavioral: prehabilitation
Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery

Experimental: PREHAB-NEOADJ

PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY

Behavioral: prehabilitation
Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery

Outcome Measures

Primary Outcome Measures

  1. Comprehension Complication Index (CCI) [through study completion, an average of 1 yea]

    Morbidity after surgery of rectal cancer: CCI - value 0-100

Secondary Outcome Measures

  1. 6 minutes walking test (6MWT) [through study completion, an average of 1 yea]

    Walking test that helps calculation of the number of daily steps to be carried out (5.000 to 10.000) daily steps

  2. Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale [through study completion, an average of 1 yea]

    Calculation of level of anxiety or depression in mild, moderate or severe. Allows referral of the patient to the psychology service

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient with rectal tumour and selected to initiate NRCT

  • Patient must know the study and sign informed consent.

  • Patient must accept the conditions necessaries to carry out the prehabilitation.

Exclusion Criteria:
  • Refusal of the patient to sign the informed consent.

  • Baseline pathology that makes it impossible to carry out prehabilitation.

  • Progression of the disease during the study period.

  • Emergency surgery.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laura Mora López Sabadell Barcelona Spain 08208

Sponsors and Collaborators

  • Corporacion Parc Tauli

Investigators

  • Principal Investigator: Laura Mora, Dr, Parc Tauli University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Laura Mora-Lopez, PhD, MD, Colorrectal Surgeon, Associate Professor, Corporacion Parc Tauli
ClinicalTrials.gov Identifier:
NCT05286086
Other Study ID Numbers:
  • PREHAREC
First Posted:
Mar 18, 2022
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Laura Mora-Lopez, PhD, MD, Colorrectal Surgeon, Associate Professor, Corporacion Parc Tauli
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 18, 2022